Abstract 1580P
Background
In the US, 5 most common advanced/metastatic (met/adv) solid tumors are metastatic non-small cell lung cancer (mNSCLC), metastatic breast cancer (mBC), metastatic prostate cancer (mPC), metastatic colorectal cancer (mCRC), and metastatic pancreatic cancer (mPanC). Current guidelines recommend NGS testing for pts with these malignancies due to approved life-prolonging therapies for pts with driver mutations. However, large cohort studies evaluating disparities in NGS testing have not been reported. Herein, we investigated the effect of SDOH on disparities in NGS testing in these tumors.
Methods
In this IRB-approved retrospective study, pt-level data were extracted from the nationwide Flatiron Health electronic health record (EHR)-derived de-identified database. Inclusion criteria: pts diagnosed with mNSCLC, mBC, mPC, mCRC, and mPanC between 2018 and 2022, with available treatment information. Disparities in the rates of NGS testing were assessed by socioeconomic status (SES), race-ethnicity (R/E), region, and insurance were assessed using Fine and Grey’s modified Cox proportional hazard model with NGS testing as the event of interest and death as a competing risk. Different baseline hazards by the year of met/adv diagnosis were assumed. Complete case analysis was performed for each analysis. All analysis was done using R v.4.2.3.
Results
The analytic cohort included 21964, 9872, 3560, 10942, and 4945 pts with mNSCLC, mBC, mPC, mCRC, and mPanC, respectively. Pts with lower SES were less likely to receive NGS testing. Results are summarized in the table. Further disparities in NGS testing by R/E, insurance type, and region will be presented in the meeting. Impact of SES on NGS testing (HR>1 indicates more NGS testing). Table: 1580P
| Cancer SES | mNSCLCn=21964 | mBCn=9872 | mPCn=3560 | mCRCn=10942 | mPanCn=4945 |
| 5 –High (reference) | HR (95% CI) | ||||
| - | - | - | - | - | |
| 4 | 0.97 (0.93 – 1.01) p=0.13 | 1.02 (0.94 – 1.11) p=0.58 | 0.99 (0.89 – 1.10) p=0.80 | 1.05 (0.99 – 1.11) p=0.11 | 1.05 (0.96 – 1.14) p=0.28 |
| 3 | 0.91 (0.87 – 0.95) pConclusionsOur findings suggest that pts with lower SES were less likely to get NGS testing, potentially reducing access to life-prolonging therapies. These results highlight the need for policies to mitigate this disparity. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyThe authors. FundingHas not received any funding. DisclosureS. Roy: Financial Interests, Research Grant: Prostate Cancer Foundation, Swim Across America Foundation; Financial Interests, Speaker, Consultant, Advisor: Varian Medical Systems. B.L. Maughan: Financial Interests, Speaker, Consultant, Advisor: AbbVie, Pfizer, AVEO oncology, Janssen, Astellas, Bristol Myers Squibb, Clovis, Tempus, Merck, Exelixis, Bayer Oncology, Lilly, Sanofi, Telix, Xencor, NCCN, Peloton Therapeutics; Financial Interests, Research Funding: Exelixis, Bavarian-Nordic, Clovis, Bristol Myers Squibb. U. Swami: Financial Interests, Personal, Writing Engagement: Astellas; Financial Interests, Personal, Advisory Board: SeaGen, Exelixis, AstraZeneca, Adaptimmune, Gilead, Imvax, Pfizer, Sanofi; Financial Interests, Institutional, Research Grant: Janssen, Exelixis; Financial Interests, Institutional, Local PI: Astellas/Seattle Genetics. N. Agarwal: Financial Interests, Personal, Invited Speaker, Invited speaker: Medscape; Financial Interests, Personal, Invited Speaker, Invited Speaker: Onclive, Research to Practice, Clinical Care Options; Financial Interests, Institutional, Other, I serve in the leadership of my cancer center (Huntsman Cancer Institute, University of Utah. Salt Lake City, UT, USA). There are multiple research projects sponsored by these companies which pay money to my institution: Arnivas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GSK, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, Telix, Tracon.; Financial Interests, Steering Committee Member, I am involved in the steering committee of the trials sponsored by these pharmas with no personal honorarium: AstraZeneca, Calithera, Crispr, Eli Lilly, Exelixis, Immunomedics, Merck, Pfizer,; Financial Interests, Steering Committee Member, I am involved in the steering committee of the trials sponsored by these pharma companies with no personal honorarium: Merck, Nektar, New Link Genetics, Oric, Pfizer, Prometheus, Rexahn, Takeda, Telix,Tracon; Financial Interests, Trial Chair, One of the two co-chairs of the clinical trials sponsored by these pharma companies. I have not received any honorarium for these roles.: Pfizer, Exelixis, Janssen, Telix.; Non-Financial Interests, Member, I am a long-standing member of ASCO and a volunteer. I was awarded the fellow of ASCO in 2023. I also act as the editor of the ASCO Daily News as a volunteer.: Amercian Society of Clinical Oncology; Non-Financial Interests, Member, I am a member of this NCI and NCTN-sponsored cooperative clinical trial network group: SWOG; Non-Financial Interests, Member, I am a member of these professional organizations.: AACR, AUA, PCF. All other authors have declared no conflicts of interest. Resources from the same session1563P - Increasing the earlier detection of lung cancer: A toolbox for changePresenter: Helena Wilcox Session: Poster session 10 1564P - Limited participation in breast cancer screening among low-SES women: A matter of engagement or of health literacy?Presenter: Allegra Ferrari Session: Poster session 10 1566P - Optimizing participation in lung cancer screening program: Results from the first round in ILYAD study in Lyon University HospitalPresenter: Emmanuel Grolleau Session: Poster session 10 1567P - Physicians' adenoma detection rate and the risk of colorectal cancer in sequential screening programs: An observational cohort studyPresenter: Li Xie Session: Poster session 10 1568P - Challenges in pilot lung cancer screening in Vojvodina, SerbiaPresenter: Jelena Djekic Malbasa Session: Poster session 10 1569P - Secondary delay in breast cancer diagnosis and role of rural medical practitioners: A cause and cure finding studyPresenter: Rahul Agarwal Session: Poster session 10 1570P - Factors and impacts of delayed presentation for county-level patients with breast cancer in a real-life setting in ChinaPresenter: Yinghua Ji Session: Poster session 10 1571P - The reasons that motivate a change of specialties among oncology residentsPresenter: Christophe Ducrocq Session: Poster session 10 1572P - Factors associated with career choice in oncology among medical studentsPresenter: Nicolas Penel Session: Poster session 10 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|